In defense of steroids [5]

American Journal of Transplantation

Volumn 5, Issue 9, 2005, Pages 2334-2335

  Steiner, Robert W ^a,b  

^a UCSD MEDICAL CENTER   (United States)

^b San Diego Imaging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; STEROID; TACROLIMUS; CORTICOSTEROID;

GRAFT SURVIVAL; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LETTER; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT WITHDRAWAL; DRUG EFFECT; GRAFT REJECTION; METHODOLOGY; NOTE; RISK; SURVIVAL; TIME;

ADRENAL CORTEX HORMONES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; RISK; STEROIDS; SURVIVAL ANALYSIS; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 27844501650     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.01027.x     Document Type: Letter

References (12)

1. Opelz G, Dohler B. Laux Gunter for the collaborative transplant study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005; 5:720-728.
2. Hricik Donald E. Steroid withdrawal for the (selected) masses. Am J Transplant 2005; 5: 639-640.
3. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Can Med Assoc J 1992; 147: 645-657.
4. Curtis JJ, Galla JH, Woodford SY, Saykaly RJ, Luke RG. Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study. Am J Kidney Dis 1981; 1: 166-171.
5. Cole E, Keown P, Landsberg D et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients. Transplantation Feb 1998;65: 505-510.
6. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation Dec 1998; 66: 1736-1740.
7. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mychopenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation Mar 2000; 69: 834-841.
8. Steiner RW. Questionable long-term benefit of mycophenolate. Transplantation Jul 2000; 70: 401-402.
9. 1 formulation. Bio Drugs 2001; 15:279-290.
10. Wassner SJ, Malekzadeh NH, Pennisi AJ et al. Allograft survival in patients receiving anticonvulsant medications. Clin Nephrol 1977; 8: 293-297.
11. Dhingra RK, Sprague SM, Ojo AO, Leavey SF. Post transplant bone disease: a case illustrating dramatic improvements in bone density with vitamin D replacement therapy. Transplantation 2001; 71: 1856-1859.
12. Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868-871.